The oral mucositis is a common inflammation in patients with
malignant neoplasms, undergoing antineoplastic therapy; its
symptoms predispose the oncological patient to various
serious complications. Its incidence is 75–100% among patients
who perform hematopoietic stem cell transplantation; 40–85% of incidences occur in patients during chemotherapy
and/or radiotherapy 

The toxicity caused by antineoplastic agents generates an in ammatory response mediated by reactive oxygen species, proinflammatory cytokines, interleukin-1, interleukin-11, and interleukin-6, which harm not only the tissues but also adjacent cells, causing injury in mucosal cells and thus reducing the epithelial thickness, resulting in ulcers